The report maintains an ADD rating with a target price of INR 2,610 (34x Q2FY29E, implying EV/E at 21x), citing focus on chronic-led growth, BSV scale-up, consumer wellness turnaround, and the long-term CAR-T bet via ACTx acquisition.
Read this note →Mankind Pharma Limited
NSE MANKIND BSE 543904 INE634S01028
0 filings · 0 analysed
2,668.30
+8.63%
over 5 years
-
Mankind Pharma Update Oct26 HSIE
The report maintains an ADD rating with a target price of INR 2,610 (34x Q2FY29E, implying EV/E at 21x), citing focus on chronic-led growth, BSV scale-up, consumer wellness turnaround, and the long-term CAR-T bet via ACTx acquisition.
-
Equity Morning Report 27th Oct 2026
The note lists MANKIND under long build-up in the market monitor section.
-
The report states Mankind Pharma's revenue grew 17.3% YoY to Rs 4,338 crore, beating estimates, with net profit up 39% YoY and the stock trading at 26.5x FY29E EPS.
-
HSIE Results Daily 27 Oct 26 HSIE
The report says EBITDA grew 27% YoY on 17% sales growth and margin expansion, with India formulation expected to outperform IPM in H2FY27 and margin guidance of 25.5-26.5% retained, with the TP revised to INR 2,610.
-
Daily Derivative and Technical snapshot 22 10 2026
The report lists Mankind Pharma under short covering with price up 1.12% and OI down 3.63%.
-
The Smart Charts section shows the Mankind Pharma buy call as stopped out, down 5.86% from entry.
-
The Smart Charts section lists an open Buy call on MANKIND from Oct 12, 2026 with stop loss 2315, targets 2525 and 2640, currently at -2.63% P/L.
-
The Smart Charts section lists an open Buy call on Mankind Pharma with stop loss 2315.00 and targets of 2525.00 and 2640.00.
-
Under Smart Charts, the note lists an open Buy call on Mankind from 12 Oct with stop loss 2315 and targets 2525/2640, currently showing a -1.61% potential P/L.
-
The Smart Charts section lists an open Buy call on Mankind from Oct 12 with stop loss 2315 and targets 2525/2640.
-
Pharma and Healthcare Q2FY27 Preview HSIE
The report expects 13% YoY revenue growth and margin expansion on better sales mix and cost controls, naming it a strong performer.
-
The report cites Mankind as one of its top ideas for superior execution, forecasting sales growth of 13.3% YoY and PAT growth of 33.1% YoY.
-
The note mentions Mankind Pharma gained alongside other pharma stocks after the US granted tariff exemptions on speciality drugs.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 27 Oct 2026, 06:56 | long | 2,312.00 | 2,610.00 | 2,540.00 | 77% | open by 2027-10-27 |
| Sharekhan (Mirae Asset Sharekhan) | 13 Oct 2026, 17:23 | long | 2,372.00 | 2,640.00 | 2,540.00 | 63% | open by 2027-10-13 |
| Sharekhan (Mirae Asset Sharekhan) | 12 Oct 2026, 16:35 | long | 2,400.00 | 2,525.00 | 2,502.50 | 82% | hit |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 2,500.00 | 2,850.00 | 2,540.00 | 11% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The note lists MANKIND under long build-up in the market monitor section.
Read this note →The report states Mankind Pharma's revenue grew 17.3% YoY to Rs 4,338 crore, beating estimates, with net profit up 39% YoY and the stock trading at 26.5x FY29E EPS.
Read this note →The report says EBITDA grew 27% YoY on 17% sales growth and margin expansion, with India formulation expected to outperform IPM in H2FY27 and margin guidance of 25.5-26.5% retained, with the TP revised to INR 2,610.
Read this note →The report lists Mankind Pharma under short covering with price up 1.12% and OI down 3.63%.
Read this note →The Smart Charts section shows the Mankind Pharma buy call as stopped out, down 5.86% from entry.
Read this note →The Smart Charts section lists an open Buy call on MANKIND from Oct 12, 2026 with stop loss 2315, targets 2525 and 2640, currently at -2.63% P/L.
Read this note →The Smart Charts section lists an open Buy call on Mankind Pharma with stop loss 2315.00 and targets of 2525.00 and 2640.00.
Read this note →Under Smart Charts, the note lists an open Buy call on Mankind from 12 Oct with stop loss 2315 and targets 2525/2640, currently showing a -1.61% potential P/L.
Read this note →The Smart Charts section lists an open Buy call on Mankind from Oct 12 with stop loss 2315 and targets 2525/2640.
Read this note →The report expects 13% YoY revenue growth and margin expansion on better sales mix and cost controls, naming it a strong performer.
Read this note →The report cites Mankind as one of its top ideas for superior execution, forecasting sales growth of 13.3% YoY and PAT growth of 33.1% YoY.
Read this note →The note mentions Mankind Pharma gained alongside other pharma stocks after the US granted tariff exemptions on speciality drugs.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief